Cellics Therapeutics, Inc. (Cellics) was founded by UC San Diego professor Liangfang Zhang based on his award-winning Cellular Nanoparticle (CNP) Technology. Cellics was created with the goal of applying the CNP Technology to treat and prevent diseases.
The mission of Cellics is to employ innovative biomimetic nanomedicines to address serious diseases with a high unmet medical need. The company’s initial primary focus is on autoimmune and inflammatory diseases and hard-to-treat infectious diseases. Additionally, Cellics is seeking to develop best-in-class vaccines for various diseases. The company has received IND allowance for its lead drug product CTI-005 for patients hospitalized with methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-sensitive Staphylococcus aureus (MSSA) pneumonia. With the IND allowance, the company plans to start the clinical trial, which will be a multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a trial investigating the safety and potential efficacy of CTI-005 in MRSA and MSSA pneumonia patients. It is the passion and goal of Cellics to use advanced technology to help human beings live healthier and longer lives.